Drug profile · INN
lenalidomide
LENALIDE
lenalidomide (LENALIDE) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lenalidomide
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 4
- Programs
- 65
- Data quality
- 0.89
Quick answer
lenalidomide (LENALIDE) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
CRL4(CRBN) E3 ubiquitin ligase inhibitor
Primary target: CRL4(CRBN) E3 ubiquitin ligase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11253591
Combination of lenalidomide and polypeptide construct, and uses thereof
granted -
US 10342869
Compositions comprising anti-CD38 antibodies and lenalidomide
granted -
US 10232041
Combination of lenalidomide and polypeptide construct, and uses thereof
granted -
US 9636334
Combination of lenalidomide and polypeptide construct, and uses thereof
granted
Frequently asked questions
What is lenalidomide?
lenalidomide (LENALIDE) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lenalidomide?
LENALIDE is a marketed brand name for lenalidomide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lenalidomide?
lenalidomide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.